It just needs to be consistent and built around the right ingredients
Until recently, the most effective new obesity medications, including semaglutide (Wegovy) and tirzepatide (Zepbound), were available only as injectables
Mounjaro, which, like Zepbound is also tirzepatide-based, saw 71% growth
A reliable AI workflow needs to preserve context: brand versus molecule : Ozempic and Wegovy are both semaglutide, but not the same market object single versus dual agonist : tirzepatide is not simply another semaglutide brand indication : diabetes, obesity, and cardiovascular risk reduction are different analytic frames funding status : PBS and private-pay populations can behave very differently time period : a 2023 shortage-period record is not equivalent to a 2026 post-shortage record source type : TGA, PBS, PBAC, company releases, media reporting, and clinical trials have different evidentiary roles The main AI risk is not that a model cannot summarise GLP-1 information
This conversation should also address realistic expectations for weight loss or glycemic improvement, potential side effects, and the commitment required for ongoing monitoring and medication adherence
Zhou X, Wang X, Sun Q, Zhang W, Liu C, Ma W, et al
